News

Bristol-Myers Squibb: Buy The Weakness

Bristol-Myers Squibb offers strong cash flow, solid growth, and a high yield despite pricing pressure and pipeline risks.

‘We will work collaboratively’: Big Pharma admits it is discussing Trump’s plan to lower drug prices

Pfizer CEO says drugmakers ‘are all ready to roll up their sleeves and execute’ as president demands more direct-to-consumer ...
Medpage Today on MSN1d

Trispecific Antibodies Emerging in Multiple Myeloma

Building on bispecific antibodies, four of which have been approved by the FDA to treat relapsed/refractory multiple myeloma, ...

Pfizer raises 2025 profit forecast as cost-cutting program gains traction

Pfizer said its full-year profit should benefit from cost cuts across its research and manufacturing operations after posting ...

Bristol-Myers Squibb: Declines Have Gone Too Far

Bristol-Myers Squibb sees stabilizing sales, growth in key drugs, and raised guidance. Click to read more about why BMY is an ...

Bristol Myers Squibb Cuts Full-Year Adjusted View, but Raises Revenue Expectations

Bristol Myers Squibb trimmed its full-year adjusted earnings view as it reported lower second-quarter earnings due to a ...

Bristol-Myers Squibb shares rise as Q2 results boosted by growth portfolio

Bristol-Myers Squibb reported second-quarter earnings that exceeded analyst expectations, driven by strong performance across ...

Bristol Myers Squibb Co. stock underperforms Thursday when compared to competitors

Shares of Bristol Myers Squibb Co. BMY slid 5.81% to $43.31 Thursday, on what proved to be an all-around dismal trading ...

Bristol Myers tops revenue expectations on strength of older drugs, shares fall

Bristol Myers Squibb posted much better-than-expected second-quarter results on Thursday on strong sales of its best-selling ...

Bristol Myers Posts Better-Than-Expected Second Quarter Results on Strength of Top Sellers

(Reuters) -Bristol Myers Squibb posted much better-than-expected second-quarter results on Wednesday on strong sales of its ...

Morgan Stanley Maintains a Sell Rating on Bristol-Myers Squibb Company (BMY)

Bristol-Myers Squibb Company (NYSE:BMY) is one of the top cheap pharmaceutical stocks to buy now. Morgan Stanley analyst ...

Bristol-Myers Squibb (BMY) Sees Healthy Momentum in Growth Portfolio in Q2 2025

Bristol-Myers Squibb Company (NYSE:BMY) is one of the Best 52-Week Low Blue Chip Stocks to Buy Now. On July 31, the company reported results for Q2 2025, wherein it saw healthy momentum throughout its ...